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Introduction: Niemann-Pick disease type C is a rare genetic lysosomal storage disease associated with impaired
intracellular lipid trafficking and a range of progressive neurological manifestations. The influence of seizure activity
on disease course and response to miglustat therapy is not currently clear.
Case presentation: Niemann-Pick disease type C homozygous for NPC1 mutation p.S940L [c. 2819 C>T] was
diagnosed in a four-and-a-half-year-old Norwegian Caucasian girl. The patient, who died at eight years and seven
months of age, had a history of prolonged neonatal jaundice and subsequently displayed progressive neurological
manifestations that started with delayed speech, ataxia, and gelastic cataplexy. A regimen of 100mg of miglustat
three times a day was initiated when she was four years and 11 months old. She showed decreased neurological
deterioration during about three and a half years of treatment. However, she displayed periods of distinct
worsening that coincided with frequent epileptic seizures. Anti-epileptic therapy reduced seizure frequency and
severity and allowed re-stabilization of her neurological function. Prior to her death, which was possibly due to
acute cardiac arrest, seizure activity was well controlled.
Conclusions: Miglustat delayed the expected deterioration of neurological function in this patient with
p.S940L-homozygous late-infantile-onset Niemann-Pick disease type C and provided important quality-of-life
benefits. This case demonstrates the importance of effective seizure control therapy in achieving and maintaining
neurological stabilization in Niemann-Pick disease type C.
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Niemann-Pick disease type C (NP-C) is a potentially
devastating progressive neurodegenerative disease cur-
rently estimated to occur in 1:100,000 to 1:120,000 live
births [1]. NP-C is caused by autosomal recessive muta-
tions in both alleles of either the NPC1 gene, which is
detected in 95% of cases, or the NPC2 gene [2]. These
mutations give rise to impaired intracellular lipid traf-
ficking and subsequent accumulation of unesterified
cholesterol, sphingosine, and a range of glycosphingoli-
pids in various tissues, including the brain [1].
NP-C has an extremely heterogeneous clinical presen-
tation characterized by a wide range of systemic,* Correspondence: johannes.skorpen@helse-mr.no
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reproduction in any medium, provided the orneurological, and psychiatric symptoms, many of which
are not specific to the disease [3]. This makes it difficult
to establish an early diagnosis. Patients may present dur-
ing infancy, but many cases present during adolescence
or adulthood [1,3]. Clinical NP-C phenotypes can be
broadly defined on the basis of age at disease onset [3].
Until recently, no disease-modifying therapy was avail-
able for NP-C. In 2009, miglustat (Zavesca, Actelion
Pharmaceuticals Ltd., Allschwil, Switzerland) was
approved in Europe for the treatment of adults and chil-
dren with NP-C on the basis of clinical trial data and a
retrospective observational cohort study showing
improvements or stabilization of neurological disease
manifestations [4-7]. To date, no published reports have
assessed the influence of seizure activity on disease
course in NP-C or the possible impact of seizures on pa-
tient responses to miglustat therapy. We report the casel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nificant seizure activity and was treated with miglustat
and anti-epileptic therapy.Case presentation
The patient was a girl born to Norwegian Caucasian par-
ents following a normal pregnancy and birth; her birth
weight was 3.44kg. As a neonate, she had jaundice that
persisted for three months and that was considered to
be due to breast feeding/breast milk icterus. No clinical
signs of hepatomegaly or splenomegaly were noted, and
further investigations, including abdominal ultrasound,
were not performed. After an initial assessment, she
showed normal healthy psychomotor development and
was walking independently at 12 months of age.
Follow-up was initiated locally when she was about two
and a half years old because her speech development was
delayed. When referred to the pediatric department at the
age of two years and 11 months, she showed slowing of
motor development, impaired balance and coordination,
episodes of gelastic cataplexy, and arrested language and
psychomotor development. Findings from brain magnetic
resonance imaging (MRI), electroencephalogram, urine/
plasma metabolic screens, and cerebrospinal fluid analyses
were all normal. Clinical examination revealed no signs of
hepatosplenomegaly.
She developed swallowing difficulties at three years
and four months, at which time her fine motor skills
had deteriorated further and included visible tremor.
Vertical gaze palsy and ataxia were detected two months
later, and her cataplectic episodes continued. Language
testing showed pronounced deficits in speech. By the
age of four years, her swallowing difficulties had notice-
ably worsened and she was losing further fine and gross
motor skills, commencing the use of a walker to ambu-
late indoors and a wheelchair for outdoor ambulation.
Her cognitive function was also significantly impaired,
and repeat language testing indicated ongoing deterio-
ration in speech. MRI analysis at the age of four years
and seven months showed deep bilateral cerebral white-
matter signal hyperintensities – a leukodystrophy-like
pathology.
The rapidly deteriorating disease prompted a search
for a specific diagnosis. The combination of cataplectic
episodes, progressive ataxia, and a notable vertical gaze
palsy ultimately provoked suspicion of possible late-
infantile NP-C. When she was four years and eight
months old, a diagnosis of NP-C was confirmed on the
basis of filipin staining and cholesterol esterification
assay findings. Genetic analysis later that year showed
homozygous p.S940L (c. 2819 C>T) mutations in the
NPC1 gene. Both parents were heterozygous for this
mutant allele.A regimen of 100mg of miglustat three times a day was
commenced when our patient was four years and 11
months old, and regular follow-up was conducted until
her death at the age of eight years and seven months; the
total treatment period was three years and eight months.
Before initiation of miglustat, a low-carbohydrate diet was
implemented to reduce potential gastrointestinal distur-
bances. This diet was gradually phased out after four
months of therapy. No gastrointestinal disturbances have
been reported during miglustat therapy, possibly because
of the early implementation of this low-carbohydrate diet.
At follow-up after one month on miglustat, our pa-
tient, who was five years old, showed continued deterio-
ration in motor function in comparison with findings six
months earlier. She was increasingly tired, and signs of
spasticity were developing in her lower extremities.
However, she displayed a noticeable improvement in
chewing and swallowing function, and her overall aware-
ness and concentration were improved.
Follow-up after six months on miglustat detected a
general improvement in motor function. At 13-month
follow-up, when she was six years old, her sitting balance
and posture and both indoor and outdoor assisted am-
bulation were improved. Her gaze was also more stable,
and she was continent for both urine and feces – a new
skill. She no longer coughed or choked while drinking
water. However, she showed gradually less interest in
food, and it was decided that a gastrostomy tube should
be established.
A general loss of energy and overall function that
coincided with an increased frequency of epileptic
attacks was observed about two and a half years ago.
Concerted anti-epileptic treatment, which is described in
detail below, significantly reduced the number of epilep-
tic episodes, and she gradually improved to become
medically stable. Although her functional abilities were
variable, she was generally continent and was eating,
drinking, sitting, and ambulating well. Two years ago,
when she was seven years old, she experienced another
period of frequent epileptic attacks and concurrent
breathing difficulties with massive overproduction of
mucus. As a result, she was temporarily hospitalized and
during that time she again displayed a generalized de-
terioration in function. Control of her seizures was re-
established about two months later, and anti-asthmatic
therapy was reinforced. Within a short time, she showed
signs of recovery and had retained her cognitive
function.
Her function across four key parameters of neurological
disease progression in NP-C – ambulation, manipulation,
language, and swallowing – was assessed by using a pub-
lished disease-specific disability scale modified to rate
function across each domain from zero, indicating the
best, to one, indicating the worst [7]. Disability
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mately every six months from the time of our first data
collection two years ago and retrospectively at time points
before that. Overall, data from disability scale assessments
were available between the ages of three years and eight
and a half years for a total follow-up period of five and a
half years and reflected the changes recorded on the basis
of empirical clinical observations (Figure 1).
Composite disability scores indicated sequential wor-
sening during the 17 months before initiation of miglu-
stat therapy, increasing from 0.13 when our patient was
36 months old to 0.65 at the last pretreatment assess-
ment, when she was about four and a half years old.
After miglustat was started, scores leveled off for about
17 months, remaining at 0.63 when she was five years
old up to the first period of frequent epileptic attacks,
when she was about six and a half years old, after which
there was some worsening (Figure 1). Assessment four
months later indicated a return toward stable disease,
with a score of 0.71. Overall, these changes were dictated
mainly by ambulation, manipulation, and swallowing
function; speech had reached the near-maximal degree
of impairment measurable before miglustat was started.
During the second period of increased epileptic activity,
when she was seven years old (Figure 1), her composite
disability score increased to the maximum level of 1, in-
dicating severe disability across all subscores. Her ambu-
lation and language scores fell back to 0.88 when her
epileptic episodes were once again under control three
months later, but her manipulation and swallowing dis-
abilities remained at 1, indicating permanent losses ofFigure 1 Composite Niemann-Pick disease type C disability scale scor
scores on the modified Niemann-Pick disease type C disability scale [7] are
Disability scale assessments were performed by the author together with a
when the patient was six years and nine months old, to when she was eig
nine months were evaluated retrospectively on the basis of patient recordsfunction. Her remaining swallowing function was used
only for tasting of food, not for feeding. There was no
change in disability scale scores during follow-up clinical
assessments afterward.
During the last clinical assessment before her death,
she was awake and alert and interested in her surround-
ings, family members, teachers, and friends. Her disabil-
ity scale score remained stable. While her ambulation
and non-verbal communication were less frequent, she
still conducted these activities in a purposeful manner.
She also retained some function in terms of simple ma-
nipulation movements such as touching and reaching,
raising arms, and assisting in feeding. On two separate
occasions, seven weeks and three weeks prior to her
death, she was hospitalized because of acute lung infec-
tions, which were resolved with treatment. Her precise
cause of death is not known. She had no prevailing
breathing difficulties or mucus overproduction and no
signs of ongoing infection. An acute cardiac arrest can-
not be ruled out.
Throughout her care, a rigorous approach was
required to control her cataplexy and seizure activity.
Initial treatment of her cataplexy with a daily dose of
5mg of fluoxetine when she was four years and nine
months old reduced the frequency and severity of epi-
sodes by about 70%. However, fluoxetine was stopped
when anti-epileptic treatment with 0.125mg of clonaze-
pam three times a day was commenced following the
onset of epilepsy with a long-lasting generalized tonic-
clonic seizure. After two months, clonazepam was
replaced by levetiracetam at doses gradually increasede during about five and a half years of follow-up. Composite
rated from zero, indicating the best, to one, indicating the worst.
child physiotherapist during planned follow-up visits at hospital from
ht years and five months old. Disability scores before age six years and
. FEA: frequent epileptic attacks.
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provided adequate seizure control for about six months
until the first period of frequent epileptic attacks about
two and a half years ago. Control was re-established ini-
tially by using 3.75mg of oral nitrazepam per day fol-
lowed by maintenance therapy with a combination of
levetiracetam and 7.5 to 10mg of clobazam per day.
After the second period of frequent epileptic attacks two
years ago, control was re-established by adding 250mg
of valproic acid twice a day to her existing combination
therapy. After this, she was clinically seizure-free for
more than a year. During the months prior to her death
she had four to six seizures each week, lasting 10 to 30
seconds. But it was not considered that this activity
required any alteration to her anti-epileptic therapy.Discussion
This case report concerns the first known patient diag-
nosed as being homozygous for the NPC1 gene muta-
tion, p.S940L. To the best of our knowledge, the clinical
phenotype for homozygous p.S940L NP-C has not been
described before. The course of progressive neurological
symptoms in our patient, preceded by initial isolated
neonatal jaundice, is in agreement with previous data on
the natural history of late-infantile-onset NP-C [1,8,9].
However, the absence of hepatomegaly or splenomegaly
in a patient with late-infantile onset is unusual. Although
no specific ultrasound examinations were performed to
assess the liver or spleen before diagnosis, repeated ab-
dominal assessments since diagnosis showed only mildly
increased spleen size. It cannot be stated for sure
whether the absence of organomegaly represents a fea-
ture specific to homozygous p.S940L NP-C or whether
the time window during which it was clinically measur-
able was missed.
In line with published data in childhood-onset NP-C,
miglustat appeared effective in stabilizing neurological
disease in our patient [6,8]. During about three and a
half years on miglustat, her rate of neurological deterior-
ation was notably slower compared with the steady pro-
gression observed before therapy. While her epilepsy
and occasional serious respiratory infections led to peri-
ods of deterioration, she regained a number of her previ-
ous levels of function a number of times.
Disease stabilization is widely viewed as an important
therapeutic outcome in NP-C [1,3] and was well repre-
sented in our patient on the basis of the disability scale
assessments. However, even though the disability scale
used here is based on empirical multidisciplinary clinical
observations [10], due caution should always be adopted
in assessing the clinical meaning of such retrospective
analyses – prospective assessments offer much greater
objectivity.The age of this patient and the timescale of follow-up
assessments largely precluded a quantitative, objective
longitudinal analysis of her cognitive function. However,
while she displayed early signs of serious cognitive im-
pairment before therapy, her concentration and respon-
siveness improved after starting miglustat, and her
overall cognitive function appeared intact even after per-
iods of frequent epileptic episodes. The observed effects
of miglustat on neurological and cognitive function were
of great importance to her parents and other caregivers.
It seems clear that intercurrent illnesses require rigor-
ous treatment in parallel with disease-specific therapy in
order to maintain quality of life in patients with late-
infantile-onset NP-C. Our patient’s repeated respiratory
infections and ensuing breathing difficulties had an im-
portant impact on her everyday well-being. She also
experienced pronounced overproduction of mucus,
which was successfully alleviated by using scopolamine
skin patches together with saline inhalations and anti-
asthmatic therapy.
Seizures are common among patients with late-infantile-
and juvenile-onset NPC, but the type, progression, and
response to therapy vary considerably. It is important to
distinguish between cataplectic and epileptic episodes in
order to define the most appropriate therapy. The recurrent
bouts of seizure activity in our patient were believed to con-
tribute strongly to significant losses of function during the
periods of frequent epileptic attacks.
The precise processes underlying disease progression
in NP-C are not yet entirely clear, and it is beyond the
scope of this article to assess possible relationships be-
tween seizure pathology and NP-C severity. We believe
that changes in seizure activity in this case were the re-
sult of NP-C disease progression. Seizures numbering
more than 50 per day in one period and culminating in
full status epilepticus in another had a devastating im-
pact on her overall function and NP-C disability scale
score. The successful control of our patient’s seizures by
using anti-epileptic therapy resulted in a significant im-
provement and a return to a level of function that, in
our opinion, reflected the true deterioration related to
the NP-C disease process. The triple regimen of anti-
epileptic therapy that we applied appeared to provide
satisfactory and prolonged seizure control. Given this
case experience, the control of seizure activity appears
vital for the maintenance of overall health and function
in NP-C and should be a key focus in clinical
management.
Conclusions
Miglustat appears to have provided distinct therapeutic
benefits and improved quality of life in this patient with
late-infantile-onset NPC. The effect of miglustat on
neurological function and cognition was also vital for
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This patient’s history highlights the challenges posed by
serious epileptic seizure activity and respiratory disease
in the clinical management of NP-C. In particular, it is
important to effectively control seizures in order to
achieve and maintain neurological stabilization during
miglustat therapy.
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